Over the past decades, analysis of the molecular background of DLBCL has advanced through gene-expression profiling (GEP) studies allowing for the investigation of cell-of-origin (COO), MYC expression and tumor microenvironment (TME). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.